SCHEMBL29655280

SCHEMBL29655280

Nc1ncc(-c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)cc1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.49
ENPP1 P22413 1/20 0.47
PARP1 P09874 16/20 0.46
LMNA P02545 1/20 0.45
PIK3CA P42336 1/20 0.45
PARP2 Q9UGN5 3/20 0.45
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45
TPI1 P60174 1/20 0.45
TUBA1B P68363 1/20 0.45
TUBA4A P68366 1/20 0.45
TUBB4B P68371 1/20 0.45
TUBB3 Q13509 1/20 0.45
TUBB2A Q13885 1/20 0.45
TUBB8 Q3ZCM7 1/20 0.45
TUBA3E Q6PEY2 1/20 0.45
TUBA1A Q71U36 1/20 0.45
TUBA1C Q9BQE3 1/20 0.45
TUBB6 Q9BUF5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19747595 1.00 AR (0.49) ARENPP1PARP1LMNAPIK3CA
SCHEMBL29655130 0.88 AR (0.52) ARENPP1PARP1LMNAPARP2
SCHEMBL19748384 0.88 AR (0.52) ARENPP1PARP1LMNAPARP2
SCHEMBL19747601 0.87 AR (0.51) ARENPP1PARP1LMNAPARP2
SCHEMBL30089699 0.87 AR (0.51) ARENPP1PARP1LMNAPARP2
SCHEMBL29655103 0.87 PARP1 (0.53) ARENPP1PARP1LMNAPIK3CA
SCHEMBL19748904 0.87 PARP1 (0.53) ARENPP1PARP1LMNAPIK3CA
SCHEMBL19748896 0.85 AR (0.51) ARENPP1PARP1LMNAPIK3CA
SCHEMBL29655126 0.85 AR (0.51) ARENPP1PARP1LMNAPIK3CA
SCHEMBL19747598 0.85 LMNA (0.49) ARENPP1PARP1LMNAPARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12145925-B2 Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer ATLASMEDX, INC. (US) 2024-11-19 US disclosed
US-20220402894-A1 Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer ATLASMEDX, INC. 2022-12-22 US disclosed
CN-109843874-B Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer 加利福尼亚大学董事会 2022-05-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402894-A1 Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer PARP2, PARP12, PARP1 AR 2031/4885ENPP1 1493/4885PARP1 3/4885
US-12145925-B2 Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer PARP2, PARP12, PARP1 AR 2031/4885ENPP1 1493/4885PARP1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.